RecruitingNCT06024837
Performance of Spectral CT-scan in Patients With Metastatic Colorectal Cancer: a Prospective Multicentre Study
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Enrollment
100 participants
Start Date
Jun 7, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
Spectral CT is a rapidly expanding imaging modality that allows a reduction in iodine dose and irradiation compared to conventional scanning. It uses the difference in attenuation of the material according to the two different energy levels of the incident x-ray beams. The dual-energy scanner has a wide range of clinical applications, particularly in abdominal imaging.
Eligibility
Inclusion Criteria2
- Patients followed for colorectal cancer with synchronous or metachronous liver metastases and/or peritoneal carcinosis
- Patients with a curative surgical resection plan
Exclusion Criteria3
- Patients with non-metastatic colorectal cancer
- Patients treated with chemotherapy without surgical plans
- Patients with colorectal cancer with extra-hepatic and extra-peritoneal metastases alone (e.g. lung, bone)
Interventions
OTHERCT Images
Analysis of CT images of peritoneal and/or liver metastases from colorectal cancer
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06024837
Related Trials
A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks
NCT074697091 location
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT071452557 locations
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
NCT070850917 locations
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
NCT065633881 location
The AIDPRO-CRC Trial
NCT066450157 locations